SCHEMBL2467593

SCHEMBL2467593

CCOC(=O)c1nn(CC)c2c1CCCC2

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PDE4A P27815 6/20 0.46
PDE4B Q07343 6/20 0.46
PDE4C Q08493 6/20 0.46
PDE4D Q08499 6/20 0.46
TRPM2 O94759 1/20 0.41
ALDH1A1 P00352 6/20 0.41
LMNA P02545 4/20 0.41
KDM4E B2RXH2 5/20 0.40
HPGD P15428 4/20 0.40
HSD17B10 Q99714 3/20 0.40
GAA P10253 2/20 0.40
MAPT P10636 2/20 0.40
MAPK1 P28482 2/20 0.40
ALOX15 P16050 1/20 0.40
CCNA2 P20248 1/20 0.39
CDK2 P24941 1/20 0.39
CCNA1 P78396 1/20 0.39
NPSR1 Q6W5P4 1/20 0.39
BRD4 O60885 1/20 0.39
MEN1 O00255 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL17024880 0.87 LMNA (0.52) PDE4APDE4BPDE4CPDE4DTRPM2
SCHEMBL24120182 0.85 LMNA (0.39) PDE4APDE4BPDE4CPDE4DTRPM2
SCHEMBL21752581 0.85 LMNA (0.49) PDE4APDE4BPDE4CPDE4DTRPM2
SCHEMBL20224755 0.84 TRPM2 (0.38) PDE4APDE4BPDE4CPDE4DTRPM2
SCHEMBL3797225 0.84 GRM5 (0.47) TRPM2ALDH1A1LMNAKDM4EHPGD
SCHEMBL182381 0.82 CYP19A1 (0.53) ALDH1A1LMNAKDM4EHPGDHSD17B10
SCHEMBL16006803 0.82 TRPM2 (0.47) TRPM2ALDH1A1LMNAKDM4EHPGD
SCHEMBL2467456 0.82 PDE4A (0.42) PDE4APDE4BPDE4CPDE4DALDH1A1
SCHEMBL2476853 0.81 LMNA (0.43) TRPM2ALDH1A1LMNAKDM4EGAA
SCHEMBL24289261 0.81 UGCG (0.41) PDE4APDE4BPDE4CPDE4DALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3632904-B1 URAT1 INHIBITORS FOR PROMOTING URIC ACID EXCRETION JIANGSU ATOM BIOSCIENCE AND PHARMACEUTICAL CO LTD (CN) 2022-04-20 EP disclosed
US-20110311485-A1 1,2,4-OXADIAZOLE DERIVATIVES AND THEIR THERAPEUTIC USE ALMIRALL S.A. (ES) 2011-12-22 US disclosed
US-20110311485-A1 1,2,4-OXADIAZOLE DERIVATIVES AND THEIR THERAPEUTIC USE ALMIRALL S.A. (ES) 2011-12-22 US disclosed
US-20110311485-A1 1,2,4-OXADIAZOLE DERIVATIVES AND THEIR THERAPEUTIC USE ALMIRALL S.A. (ES) 2011-12-22 US disclosed
EP-2370431-A1 1, 2, 4 -OXADIAZOLE DERIVATIVES AND THEIR THERAPEUTIC USE Almirall S.A. (ES) 2011-10-05 EP disclosed
WO-2010072352-A1 1, 2, 4 -OXADIAZOLE DERIVATIVES AND THEIR THERAPEUTIC USE ALMIRALL S.A. (ES) 2010-07-01 WO disclosed
WO-2010072352-A1 1, 2, 4 -OXADIAZOLE DERIVATIVES AND THEIR THERAPEUTIC USE ALMIRALL S.A. (ES) 2010-07-01 WO disclosed
EP-2202232-A1 1,2,4-oxadiazole derivatives and their therapeutic use Laboratorios Almirall, S.A. (ES) 2010-06-30 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110311485-A1 1,2,4-OXADIAZOLE DERIVATIVES AND THEIR THERAPEUTIC USE S1PR1, S1PR2, S1PR3 PDE4A 177/4885PDE4B 176/4885PDE4C 618/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.